Retrospective validation of the laparoscopic ICG SLN mapping in patients with grade 3 endometrial cancer
- PMID: 29691646
- PMCID: PMC11813295
- DOI: 10.1007/s00432-018-2648-y
Retrospective validation of the laparoscopic ICG SLN mapping in patients with grade 3 endometrial cancer
Abstract
Purpose: To evaluate the sensitivity, negative predictive value (NPV) and false-negative (FN) rate of the near infrared (NIR) indocyanine green (ICG) sentinel lymph node (SLN) mapping in patients with poorly differentiated endometrial cancer who have undergone a full pelvic and para-aortic lymphadenectomy after SLN mapping.
Methods: We performed a retrospective analysis of patients with endometrial cancer undergoing a laparoscopic NIR-ICG SLN mapping followed by a systematic pelvic and para-aortic lymphadenectomy. Inclusion criteria were a grade 3 endometrial cancer or a high-risk histology (papillary serous, clear cell carcinoma, carcinosarcoma, and neuroendocrine carcinoma) and a completion pelvic and para-aortic lymphadenectomy to the renal vessels after SLN mapping. Overall and bilateral detection rates, sensitivity, NPV, and FN rates were calculated.
Results: From December 2012 until January 2017, 42 patients fulfilled inclusion criteria. Overall and bilateral detection rates were 100 and 90.5%, respectively. Overall, 23.8% of the patients had lymph node metastases. In one patient, despite negative bilateral pelvic SLNs, a metastatic non-SLN-isolated para-aortic metastasis was detected. This NSLN was clinically suspicious and sent to frozen section analysis during the surgery. FN rate, sensitivity, and NPV were 10, 90, and 97.1%, respectively. For the SLN mapping algorithm, FN rate, sensitivity, and NPV were 0, 100, and 100%, respectively.
Conclusions: Laparoscopic NIR-ICG SLN mapping in high-risk endometrial cancer patients has acceptable sensitivity, FN rate, and NPV.
Keywords: Carcinosarcomas; Clear cell carcinoma; Endometrial cancer; Grade 3; Sentinel lymph node biopsy; Uterine papillary serous carcinoma.
Conflict of interest statement
None of the authors have any conflict of interest.
Figures
Similar articles
-
FIGO stage IIIC endometrial cancer identification among patients with complex atypical hyperplasia, grade 1 and 2 endometrioid endometrial cancer: laparoscopic indocyanine green sentinel lymph node mapping versus frozen section of the uterus, why get around the problem?J Cancer Res Clin Oncol. 2017 Mar;143(3):491-497. doi: 10.1007/s00432-016-2303-4. Epub 2016 Nov 11. J Cancer Res Clin Oncol. 2017. PMID: 27834005 Free PMC article.
-
Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis.Minerva Ginecol. 2018 Apr;70(2):194-214. doi: 10.23736/S0026-4784.17.04179-X. Epub 2017 Nov 28. Minerva Ginecol. 2018. PMID: 29185673
-
Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99m with blue dye versus indocyanine green fluorescent dye.J Cancer Res Clin Oncol. 2017 Mar;143(3):475-480. doi: 10.1007/s00432-016-2297-y. Epub 2016 Nov 3. J Cancer Res Clin Oncol. 2017. PMID: 27812854 Free PMC article.
-
Sentinel lymph node intraoperative analysis in endometrial cancer.J Cancer Res Clin Oncol. 2020 Dec;146(12):3199-3205. doi: 10.1007/s00432-020-03356-x. Epub 2020 Aug 19. J Cancer Res Clin Oncol. 2020. PMID: 32815026 Free PMC article.
-
Indocyanine green and infrared fluorescence in detection of sentinel lymph nodes in endometrial and cervical cancer staging - a systematic review.Eur J Obstet Gynecol Reprod Biol. 2016 Nov;206:213-219. doi: 10.1016/j.ejogrb.2016.09.027. Epub 2016 Sep 30. Eur J Obstet Gynecol Reprod Biol. 2016. PMID: 27750179
Cited by
-
Controversies in the Management of Early-stage Serous Endometrial Cancer.In Vivo. 2021 Mar-Apr;35(2):671-680. doi: 10.21873/invivo.12307. In Vivo. 2021. PMID: 33622859 Free PMC article. Review.
-
The progress and prospect of sentinel lymph node mapping in endometrial carcinoma.Front Med (Lausanne). 2023 Nov 23;10:1306343. doi: 10.3389/fmed.2023.1306343. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38076272 Free PMC article. Review.
-
Sentinel Lymph Node Biopsy in Surgical Staging for High-Risk Groups of Endometrial Carcinoma Patients.Int J Environ Res Public Health. 2022 Mar 21;19(6):3716. doi: 10.3390/ijerph19063716. Int J Environ Res Public Health. 2022. PMID: 35329403 Free PMC article. Review.
-
Paraaortic sentinel lymph node detection in intermediate and high-risk endometrial cancer by transvaginal ultrasound-guided myometrial injection of radiotracer (TUMIR).J Gynecol Oncol. 2021 Jul;32(4):e52. doi: 10.3802/jgo.2021.32.e52. Epub 2021 Mar 20. J Gynecol Oncol. 2021. PMID: 33908710 Free PMC article.
-
Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation.Gynecol Oncol. 2019 Nov;155(2):365-373. doi: 10.1016/j.ygyno.2019.08.031. Epub 2019 Sep 26. Gynecol Oncol. 2019. PMID: 31500893 Free PMC article. Review.
References
-
- Ballester M, Dubernard G, Lécuru F et al (2011) Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol 12:469–476 - PubMed
-
- Barlin JN, Khoury-Collado F, Kim CH et al (2012) The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol 125:531–535 - PubMed
-
- Benedetti Panici P, Basile S, Maneschi F et al (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716 - PubMed
-
- Buda A, Papadia A, Zapardiel I, Vizza E, Ghezzi F, De Ponti E, Lissoni AA, Imboden S, Diestro MD, Verri D, Gasparri ML, Bussi B, Di Martino G, de la Noval BD, Mueller M, Crivellaro C (2016) From conventional radiotracer Tc-99(m) with blue dye to indocyanine green fluorescence: a comparison of methods towards optimization of sentinel lymph node mapping in early stage cervical cancer for a laparoscopic approach. Ann Surg Oncol 23:2959–2965 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
